1. Market Research
  2. > Pharmaceutical
  3. > Biopharmaceutical Market Trends
Biologics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Biologics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

  • May 2022
  • 181 pages
  • ID: 6283186
  • Format: PDF
  • Mordor Intelligence LLP

Summary

Table of Contents

Search Inside

The biologics market was valued at approximately USD 343.02 billion in 2021, and it is expected to reach USD 569.69 billion by 2027, registering a CAGR of 9.22% during the forecast period, 2022-2027.

With the growing COVID-19 burden, there has been a huge demand for biologics during the pandemic, which may drive the market growth. For instance, in May 2020, the National Research Council of Canada and China-based CanSino Biologics collaborated on the clinical development of a COVID-19 vaccine in Canada. The vaccine, known as Ad5-nCoV, is an adenovirus Type 5 vector-based vaccine currently in Phase II development in Wuhan, China. Thus, extensive research and development activities taking place on biologics for the treatment of COVID-19 are expected to drive the growth of the biologics market in the near future.

The market is majorly driven by growing capital investment from the key market players, the rise in the burden of chronic diseases, loss of patent exclusivity of the leading biologic drugs, and growing demand and higher acceptability for innovative therapies.

According to the World Health Organization statistics 2018, globally, chronic diseases kill more than 41 million people each year. Cardiovascular diseases account for most chronic disease deaths, or 17.9 million people annually, followed by cancers (9 million), respiratory diseases (3.9 million), and diabetes (1.6 million). These four groups account for 80% of all chronic disorder deaths. Tobacco use, physical inactivity, alcohol consumption, and unhealthy diets create a risk of dying from non-communicable diseases.? Also, the rising geriatric population is much more susceptible to chronic diseases, which helps in increasing the biologics demand.

Biologic drugs are used in the treatment of major chronic diseases, notably cancer and autoimmune diseases, which has enabled big pharmaceutical companies, like Eli Lilly and Company, Bristol-Myers Squibb, Novartis, AstraZeneca, and GlaxoSmithKline (GSK), to invest in these products. In 2019, three biological drugs were approved by the United States Food and Drug Administration (FDA), one of which is an anticoagulant solution by Griffons.

There are also increasing investments that have helped in driving the overall market growth. Novartis AG invested around USD 700 million in its biologics facility in Singapore, and Bristol-Myers Squibb invested nearly USD 900 million in an Irish large-scale biologics facility which was expected to be completed by 2019.

Furthermore, biologics prove efficient in treating rheumatoid arthritis and Crohn’s disease, which boosts the market even further.

Key Market Trends

The Cancer Segment is Expected to Dominate the Application Segment Over the Forecast Period

The cancer burden is found increasing, and cancer therapies must be modified according to regional and national priorities. The goal of biological therapy for cancer is to induce the immune system to recognize and kill cancer cells.

The COVID-19 pandemic has been found to disrupt cancer care, including delaying diagnoses and treatment and halting clinical trials. Furthermore, the healthcare systems are rapidly reorganizing cancer services to ensure that patients continue to receive essential care while minimizing exposure to SARS-CoV-2 infection. This has had a slightly negative impact, but post-pandemic, the situation is expected to get stabilized.

According to the Globocan Report 2020, globally, around 19,292,789 new cancer cases have been reported and 9,958,133 reported cancer deaths. The majorly affecting cancers are breast cancer, lung cancer, colorectum cancer, and prostate cancer. Biological therapy is used in the treatment of many types of cancers to prevent or slow tumor growth and prevent the spread of cancer. Biological therapy often causes fewer toxic side effects than other cancer treatments. The goal of biological therapy for cancer is to induce the immune system to recognize and kill cancer cells.

Market players are also continuously focusing on the development of novel biologic therapeutics for the treatment of cancer and are investing in research and development activities. For instance, in August 2019, Dr. Reddy’s Laboratories launched its bevacizumab ‘similar biologic’, Versavo (DRZ_BZ), in India. Bevacizumab is a humanized monoclonal antibody used to treat various cancers, including colorectal, lung, breast, glioblastoma, kidney, and ovarian. Hence, all these aforementioned factors have helped in the growth of the cancer segment of the market.

North America Holds the Largest Market Share and is Believed to Follow the Same Trend over the Forecast Period

The North American healthcare biologics market has dominated the global market, and it is estimated to show a similar trend during the forecast period. The primary factors driving the market are the increasing incidences of chronic diseases, the presence of well-established pharmaceutical companies, and an increase in the number of biotech companies.

With the rising COVID-19 pandemic, there are US-based companies that are racing to develop vaccines against COVID-19. For instance, in March 2020, a Phase 1 clinical trial began at Kaiser Permanente Washington Health Research Institute (KPWHRI) in Seattle to evaluate an investigational vaccine designed to protect against COVID-19. The vaccine is being developed by NIAID scientists and their collaborators at the biotechnology company Moderna Inc.

According to the estimates of the American Cancer Society, in 2018, an estimated 1,735,350 new cancer cases were diagnosed, and 609,640 people succumbed to cancer in the United States. The most common cancers in the United States are breast cancer, lung cancer, prostate cancer, colorectum cancer, bladder cancer, and skin cancer.

In August 2020, Biocon Biologics India, a fully integrated biosimilars company and a subsidiary of Biocon Ltd, and Mylan NV announced the US launch of Semglee (insulin glargine injection). Hence, all these factors are found to boost the overall market growth in the region.

Competitive Landscape

The biologics market is moderately competitive and consists of several major players. The companies are implementing certain strategic initiatives such as mergers, new product launches, acquisitions, and partnerships that help them in strengthening their market positions. These companies have made huge capital investments in the research and development of biologics as the cost of biologics is quite high.

Additional Benefits:

The market estimate (ME) sheet in Excel format
3 months of analyst support

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Grace helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Oral Biologics & Biosimilar Drugs Global Market Report 2022

  • $ 5000
  • March 2022
  • 300 pages

Major players in the oral biologics & biosimilar drugs market are Novartis, Rani Therapeutics, Eli Lilly and Co., AstraZeneca plc., Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceuticals, BiosanaPharma, ...

  • World
  • United States
  • Biopharmaceutical
  • Biosimilar
  • Industry analysis
  • Biosimilar Approvals
  • Chronic Disease Prevalence

ref:plp2022

Reportlinker.com © Copyright 2022. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on